Table 2.

Associations between oral HT categories and VTE risk

	Cases/Person-years	Age-adjusted	Multivariable-adjusted
Oral HT		HRa (95% CI)	HRb (95% CI)
HT use status
Never user	168/67962	1.00 (Ref.)	1.00 (Ref.)
Past user	173/61340	0.93 (0.75–1.16)	0.90 (0.72–1.12)
Current user	91/27740	1.87 (1.41–2.48)	1.94 (1.45–2.60)
HT type
Never user	168/67962	1.00 (Ref.)	1.00 (Ref.)
Estrogen onlyc	42/10010	2.19 (1.54–3.11)	1.91 (1.30–2.80)
Estrogen + Progestinc	46/15205	1.90 (1.32–2.73)	2.35 (1.62–3.40)
Duration of HT use
Never user	168/67962	1.00 (Ref.)	1.00 (Ref.)
< 2 years	67/26405	1.03 (0.78–1.38)	1.00 (0.75–1.33)
2+ years	197/62675	1.16 (0.94–1.44)	1.13 (0.90–1.41)
HT initiationd
Never user	168/67962	1.00 (Ref.)	1.00 (Ref.)
Early initiation	140/48007	1.40 (1.08–1.82)	1.38 (1.06–1.81)
Late initiation	124/41074	0.95 (0.75–1.21)	0.91 (0.71–1.16)

HT, hormone therapy; VTE, venous thromboembolism; HR, hazard ratio; CI, confidence interval.

^aAge-adjusted model: adjusting for age (in months).

^bMultivariable-adjusted model: adjusting for age (in months), physical activity (continuous and indicator for missing), alcohol use (continuous and indicator for missing), smoking (never, former, or current), current aspirin use (yes or no), parity (none, one, or more than one), prevalent diabetes, prevalent hypertension, prevalent hypercholesterolemia, prevalent MI/angina, prevalent cancer, hysterectomy (yes or no), and BMI (continuous and indicator for missing).

^cOnly among current HT users.

^dWe defined ‘early initiation’ if women were aged < 60 years at HT initiation or had the first use within the first 10 years of menopause and ‘late initiation’ if women were aged ≥ 60 years at initiation and had the first use ≥ 10 years after menopause onset.